ClinicalTrials.gg
CompletedNCT03900377Updated Nov 24, 2023

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

A Phase 1/2 interventional study of SyB L-0501RI in Lymphoma, B-cell, Diffuse, sponsored by SymBio Pharmaceuticals. Completed at 14 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by SymBio Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.

Enrollment
130th of 237
37 · median 44
Started
2019
the only one that year
Phase 1/2
24 of 253
none open now
Registered
239th of 253
by date

Among the 253 studies testing rituximab in Lymphoma, this one is the 130th largest by enrollment of the 237 interventional ones that give a count, is the only one that started in 2019, is one of 24 in phase 1/2, and was the 239th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies testing rituximab in Lymphoma, or all of them as a file.
02

Study summary

For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell lymphoma (MCL), and the safety and tolerability will be investigated in patients with recurrent/refractory diffuse large B-cell lymphoma (DLBCL).

03

Conditions studied

  • Lymphoma, B-cell, Diffuse

Browse trials for

Keywords

  • Lymphoma, B-cell, Diffuse, SyB L-0501RI
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For previously untreated patients with Lg-B-NHL or MCL

Inclusion Criteria

Patients who satisfy all of the conditions listed below:

▪ Patients who satisfy all of the following criteria A) to D): A) Patients who are histopathologically confirmed to have one of the following subtypes of CD20 (cluster of differentiation 20)-positive Lg-B-NHL or MCL (excluding transformed lymphoma) by lymph node or evaluable tissue biopsy (World Health Organization [WHO] histological classification [4th edition]).

  • Small lymphocytic lymphoma
  • Splenic marginal zone lymphoma
  • Lymphoplasmacytic lymphoma
  • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)
  • Nodal marginal zone lymphoma
  • Follicular lymphoma (Grade 1, 2, 3a)
  • MCL B) Patients who have at least one (>1.5 cm in major axis on computed tomography [CT]).

C) Patients without a history of treatment for lymphoma. D) Patients with at least one of the following clinical signs or symptoms (with the exception of MCL patients).

  1. Bulky disease >7 cm in major axis on CT (excluding lesions in the spleen)
  2. B symptoms

    • Unexplained fever exceeding 38.0ºC
    • Night sweats
    • Weight loss of more than 10% within 6 months before registration
  3. Elevated serum lactate dehydrogenase (LDH) or β2-microglobulin level
  4. Involvement of at least 3 regional lymph nodes >3 cm in major axis on CT
  5. Symptomatic splenomegaly
  6. Compressive symptoms
  7. Pleural effusion and/or ascites

    • Patients aged between 20 and 79 years (at the time of registration).
    • Patients who are expected to survive for at least 3 months.
    • Patients with an (ECOG) performance status (PS) of 0 to 2.
    • Patients with adequate functional reserve of major organs (bone marrow, heart, lungs, liver, kidneys, etc.).

      • : ≥1,500/mm\^3
      • count: ≥75,000/mm\^3
      • (AST) [glutamic oxaloacetic transaminase [GOT]): ≤3.0 times the institution's (ULN)
      • Alanine aminotransferase (ALT) [glutamic pyruvic transaminase (GPT)]: ≤3.0 times the institution's ULN
      • Total : \<2.0 mg/dL
      • Serum creatinine: \<2.0 mg/dL
      • Percutaneous arterial oxygen saturation (SpO2): ≥95% or Partial arterial oxygen pressure (PaO2): ≥65 mmHg
      • No abnormal findings requiring treatment on (ECG)
      • (LVEF) on echocardiography: ≥55%
    • Patients who have provided written to participate in this study.

Exclusion Criteria

Patients who meet any of the following conditions will be excluded:

  • MCL patients aged ≤65 years (at the time of registration).
  • Patients who have a history of treatment for Lg-B-NHL or MCL (chemotherapy, radiotherapy, antibody therapy or antitumor therapy).
  • Patients who have previously received hematopoietic stem cell transplantation.
  • Patients with invasion to central nervous system (CNS) or clinical symptoms suspected of CNS invasion.
  • Patients with serious active infection (requiring antibiotic, antifungal, or antiviral IV injection).
  • Patients with serious complications (such as hepatic failure and renal failure).
  • Patients with concurrent or previous, serious cardiac disease (e.g., myocardial infarction, ischemic heart disease); however, patients with arrhythmias are allowed to be enrolled if it does not require treatment at the time of registration.
  • Patients with serious gastrointestinal symptoms (such as high-grade or severe nausea/vomiting or diarrhea).
  • Patients with malignant pleural effusion, pericardial effusion, or ascites.
  • Patients positive for surface (HBs) antigen, virus (HCV) antibody, or (HIV) antibody (patients with positive hepatitis B virus [HBV]-DNA quantitative test results if they are negative for HBs antigen and positive for HBs antibody or hepatitis B core [HBc] antibody).
  • Patients with serious bleeding tendencies (such as disseminated intravascular coagulation [DIC]).
  • Patients with a fever of 38.0ºC or higher (with the exception of fever developing as a B symptom).
  • Patients with concurrent or previous interstitial pneumonia, pulmonary fibrosis, or .
  • Patients with active multiple primary cancers or patients with a history of other within the past 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or digestive organs.
  • Patients with concurrent or previous hemolytic anemia.
  • Patients who have previously received bendamustine hydrochloride.
  • Patients who have received a cytokine preparation, such as granulocyte colony- stimulating factor (G-CSF) or erythropoietin, or blood transfusions within 2 weeks before a screening test for this study.
  • Patients who have received other products or unapproved drugs within 3 months before registration for this study.
  • Patients with a history of allergy to medications similar to SyB L-0501RI (e.g., alkylating agents and purine-nucleoside derivatives).
  • Patients who cannot tolerate rituximab.
  • Pregnant, possibly pregnant, or lactating women.
  • Patients, whether male or female, who do not agree to use .

Duration:

Male patients; during the treatment period and for 6 months after treatment Female patients with no menstruation; during the treatment period Female patients with menstruation; during the treatment period and for 3 months after treatment

  • Patients with drug addiction, narcotic addiction, or alcohol dependence.
  • Patients who are unable to take pre-treatment medication due to drug allergies or the like.
  • Patients who are otherwise judged by the investigator or subinvestigator to be unsuitable as a subject.

For patients with recurrent or DLBCL

Inclusion Criteria

Patients who satisfy all of the conditions listed below:

▪ Patients who satisfy both of the following criteria A and B: A) Patients who are histopathologically confirmed to have CD20-positive DLBCL (excluding transformed lymphoma) by lymph node biopsy or evaluable tissue biopsy (WHO histological classification [4th edition]).

B) Patients with recurrent or refractory DLBCL who have had disease progression after standard rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy or R-CHOP-like therapy as treatment.

  • Patients aged between 20 and 79 years (at the time of registration).
  • Patients who are expected to survive for at least 3 months.
  • Patients with an ECOG PS of 0 to 2.
  • Patients with adequate functional reserve of major organs (bone marrow, heart, lungs, liver, kidneys, etc.).

    • Neutrophil count: ≥1,500/mm\^3
    • Platelet count: ≥75,000/mm\^3
    • AST (GOT): ≤3.0 times the institution's ULN
    • ALT (GPT): ≤3.0 times the institution's ULN
    • Total bilirubin: \<2.0 mg/dL
    • Serum creatinine: \<2.0 mg/dL
    • SpO2: ≥95% or PaO2: ≥65 mmHg
    • No abnormal findings requiring treatment on ECG
    • LVEF on echocardiography: ≥55%
  • Patients who have provided written informed consent to participate in this study.

Exclusion Criteria

Patients who meet any of the following conditions will be excluded:

  • Patients with an off-treatment interval of less than 3 weeks between the last day of preceding treatment (chemotherapy, radiotherapy, antibody therapy, or antitumor steroid therapy) for DLBCL and the day of registration for this study.
  • Patients who are judged by the investigator or subinvestigator to be suitable for peripheral blood stem cell transplantation.
  • Patients who have previously received allogeneic hematopoietic stem cell transplantation.
  • Patients who have previously received radioimmunotherapy
  • Patients with invasion to CNS or clinical symptoms suspected of CNS invasion.
  • Patients with serious active infection (requiring antibiotic, antifungal, or antiviral IV injection).
  • Patients with serious complications (such as hepatic failure and renal failure).
  • Patients with concurrent or previous, serious cardiac disease (e.g., myocardial infarction, ischemic heart disease); however, patients with arrhythmias are allowed to be enrolled if it does not require treatment at the time of registration.
  • Patients with serious gastrointestinal symptoms (such as high-grade or severe nausea/vomiting or diarrhea).
  • Patients with malignant pleural effusion, pericardial effusion, or ascites.
  • Patients positive for HBs antigen, HCV antibody, or HIV antibody (patients with positive HBV-DNA quantitative test results if they are negative for HBs antigen and positive for HBs antibody or HBc antibody).
  • Patients with serious bleeding tendencies (such as DIC).
  • Patients with a fever of 38.0ºC or higher (with the exception of fever developing as a B symptom).
  • Patients with concurrent or previous interstitial pneumonia, pulmonary fibrosis, or chronic obstructive pulmonary disease.
  • Patients with active multiple primary cancers or patients with a history of other malignancy within the past 5 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or digestive organs.
  • Patients with concurrent or previous autoimmune hemolytic anemia.
  • Patients who have previously received bendamustine hydrochloride.
  • Patients who have received a cytokine preparation, such as G-CSF or erythropoietin, or blood transfusions within 2 weeks before a screening test for this study.
  • Patients who have received other investigational products or unapproved drugs within 3 months before registration for this study.
  • Patients with a history of allergy to medications similar to SyB L-0501RI (e.g., alkylating agents and purine-nucleoside derivatives).
  • Patients who cannot tolerate rituximab.
  • Pregnant, possibly pregnant, or lactating women.
  • Patients, whether male or female, who do not agree to use contraception.

Duration:

Male patients; during the treatment period and for 6 months after treatment Female patients with no menstruation; during the treatment period Female patients with menstruation; during the treatment period and for 3 months after treatment

  • Patients with drug addiction, narcotic addiction, or alcohol dependence.
  • Patients who are unable to take pre-treatment medication due to drug allergies or the like.
  • Patients who are otherwise judged by the investigator or subinvestigator to be unsuitable as a subject.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Lg-B-NHL or MCL

    For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m\^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.

    Drug: SyB L-0501RI

  • Experimental
    DLBCL

    For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m\^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.

    Drug: SyB L-0501RI

Interventions

  • The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.

    Also known as: Rituximab

06

What researchers measure

Primary outcomes

  1. Adverse events (type, frequency, severity)

    Time frame: Up to 36 weeks

  2. Number of subjects with adverse event

    Time frame: Up to 36 weeks

  3. Number of adverse events

    Time frame: Up to 36 weeks

  4. Number of subjects with abnormality (Common Terminology Criteria for Adverse Events [CTCAE] grade ≥3) in laboratory test values

    Time frame: Up to 36 weeks

  5. Number of subjects with grade ≥3 physical examination finding

    Time frame: Up to 36 weeks

  6. Number of subjects with dose limiting toxicity in DLBCL arm

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Complete response (CR) rate

    Time frame: Up to 36 weeks

  2. Overall response rate (antitumor effect : ≥ partial response [PR])

    Time frame: Up to 36 weeks

  3. Progression-free survival (PFS)

    Time frame: Up to 36 weeks

  4. The maximum concentration (Cmax) of unchanged SyB L-0501

    Time frame: Prior to and 5, 10 min after start of administration, and 5, 15, 30, 60, 120, 240, 360 min after completion of administration on Day 1 of the 1st cycle in Lg-B-NHL or MCL Arm (in DLBCL Arm, Day 2 of the 1st cycle)

  5. The maximum drug concentration time (Tmax) of unchanged SyB L-0501

    Time frame: Prior to and 5, 10 min after start of administration, and 5, 15, 30, 60, 120, 240, 360 min after completion of administration on Day 1 of the 1st cycle in Lg-B-NHL or MCL Arm (in DLBCL Arm, Day 2 of the 1st cycle)

  6. The area under the curve (AUC) for unchanged SyB L-0501

    Time frame: Prior to and 5, 10 min after start of administration, and 5, 15, 30, 60, 120, 240, 360 min after completion of administration on Day 1 of the 1st cycle in Lg-B-NHL or MCL Arm (in DLBCL Arm, Day 2 of the 1st cycle)

  7. The half-life period (T1/2) of unchanged SyB L-0501

    Time frame: Prior to and 5, 10 min after start of administration, and 5, 15, 30, 60, 120, 240, 360 min after completion of administration on Day 1 of the 1st cycle in Lg-B-NHL or MCL Arm (in DLBCL Arm, Day 2 of the 1st cycle)

07

Study locations

14 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Ōta, Gunma, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Isehara, Kanagawa, Japan
  • Research Site
    Kurashiki, Okayama, Japan
  • Research Site
    Koto-ku, Tokyo, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Okayama, Japan
  • Research Site
    Yamagata, Japan
08

References and documents

Publications

  • Ishizawa K, Yokoyama M, Kato H, Yamamoto K, Makita M, Ando K, Ueda Y, Tachikawa Y, Suehiro Y, Kurosawa M, Kameoka Y, Nagai H, Uoshima N, Ishikawa T, Hidaka M, Ito Y, Utsunomiya A, Fukushima K, Ogura M. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. Cancer Chemother Pharmacol. 2022 Jul;90(1):83-95. doi: 10.1007/s00280-022-04442-2. Epub 2022 Jul 7. PubMed 35796785 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Sep 2020, 17 months.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 17 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Apr 3, 2019
StartActual
Apr 1, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Feb 26, 2021
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03900377
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Apr 1, 2019
Primary completion
Sep 9, 2020
Completion
Feb 26, 2021
Last update
Nov 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion